A Double-Masked, Randomized, 1-Year Study Comparing the Corneal Effects of Dorzolamide, Timolol, and Betaxolol

Abstract
DORZOLAMIDE hydrochloride is the first commercially available topical carbonic anhydrase inhibitor and has been in widespread clinical use for the treatment of elevated intraocular pressure (IOP) since May 1995. Dorzolamide is a potent inhibitor of carbonic anhydrase isoenzyme II (CA-II),1 which is found primarily in red blood cells but also in other tissues, including the ciliary processes of the eye.2 Inhibition of CA-II in the ciliary processes results in decreased aqueous humor secretion with subsequent reduction in IOP.